Phase I study of mFOLFOX-6, bevacizumab, and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer.

被引：1
|
作者：
Gilcrease, Glynn Weldon
Weis, John R.
Jones, Kimberly
Davis, Thaylon
Mitchell, Marlene
Davidson, Cynthia
Sharma, Sunil
机构：
[1] Univ Utah, Salt Lake City, UT USA
[2] Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
600
引用
收藏
页数：2
相关论文
共 50 条
  • [11] The comparison of mFOLFOX-6, mDCF, mFOLFIRINOX in the first-line treatment of advanced gastric cancer
    Ignatova, E.
    Fedyanin, M.
    Pokataev, I.
    Tryakin, A.
    Popova, A.
    Bazin, I.
    Chekini, D.
    Sekhina, O.
    Lyadova, M.
    Rumyantsev, A.
    Nikulin, V.
    Vakhabova, Y.
    Moiseenko, F.
    Chubenko, V.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S181 - S181
  • [12] A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
    Van Cutsem, E.
    Prenen, H.
    D'Haens, G.
    Bennouna, J.
    Carrato, A.
    Ducreux, M.
    Bouche, O.
    Sobrero, A.
    Latini, L.
    Staines, H.
    Oum'Hamed, Z.
    Dressler, H.
    Studeny, M.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2085 - 2091
  • [13] Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC)
    Sharma, S.
    Reid, T.
    Hoosen, S.
    Garrett, C.
    Beck, J.
    Davidson, S.
    MacKenzie, M.
    Brandt, U.
    Hecht, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [14] Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
    Yamazaki, K.
    Nagase, M.
    Tamagawa, H.
    Ueda, S.
    Tamura, T.
    Murata, K.
    Nakajima, T. Eguchi
    Baba, E.
    Tsuda, M.
    Moriwaki, T.
    Esaki, T.
    Tsuji, Y.
    Muro, K.
    Taira, K.
    Denda, T.
    Funai, S.
    Shinozaki, K.
    Yamashita, H.
    Sugimoto, N.
    Okuno, T.
    Nishina, T.
    Umeki, M.
    Kurimoto, T.
    Takayama, T.
    Tsuji, A.
    Yoshida, M.
    Hosokawa, A.
    Shibata, Y.
    Suyama, K.
    Okabe, M.
    Suzuki, K.
    Seki, N.
    Kawakami, K.
    Sato, M.
    Fujikawa, K.
    Hirashima, T.
    Shimura, T.
    Taku, K.
    Otsuji, T.
    Tamura, F.
    Shinozaki, E.
    Nakashima, K.
    Hara, H.
    Tsushima, T.
    Ando, M.
    Morita, S.
    Boku, N.
    Hyodo, I.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1539 - 1546
  • [15] A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC).
    Infante, J. R.
    Cohn, A. L.
    Reid, T. R.
    Edenfield, W. J.
    Cescon, T.
    Hamm, J. T.
    Tarazi, J. C. Ed
    Kim, S.
    Rosbrook, B.
    Cartwright, T. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [16] 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study
    Hecht, J. Randolph
    Mitchell, Edith P.
    Yoshino, Takayuki
    Welslau, Manfred
    Lin, Xun
    Maneval, E. Dna Chow
    Paolini, Jolanda
    Lechuga, Maria Jose
    Kretzschmar, Albrecht
    CANCER MANAGEMENT AND RESEARCH, 2015, 7 : 165 - 173
  • [17] Phase I trial of erlotinib (E), modified FOLFOX6 (mFOLFOX6), and bevacizumab (B) as first-line therapy for metastatic colorectal cancer (MCRC)
    Singh, D.
    Rath, L.
    Bokar, J. A.
    Brell, J. M.
    Cooney, M. M.
    Dowlati, A.
    Gibbons, J.
    Nock, C. J.
    Savvides, P.
    Krishnamurthi, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [18] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Cabebe, Elwyn C.
    Fisher, George A.
    Sikic, Branimir I.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1082 - 1087
  • [19] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Elwyn C. Cabebe
    George A. Fisher
    Branimir I. Sikic
    Investigational New Drugs, 2012, 30 : 1082 - 1087
  • [20] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
12345